How to Get Lantus (Insulin Glargine) in Ohio

What Is Insulin Glargine and Why Ohio Patients Use It

Insulin glargine is a long-acting basal insulin analog approved by the FDA for adults and pediatric patients (age 6 and older for type 1 diabetes, adults for type 2 diabetes). It provides a steady, peakless 24-hour insulin release that controls fasting blood glucose without the pronounced peaks seen with NPH insulin. In Ohio, it is dispensed most commonly as Lantus (Sanofi), the biosimilar Basaglar (Eli Lilly), or the higher-concentration Toujeo (300 units/mL, Sanofi).

The FDA approved the original Lantus label in April 2000, with the prescribing information updated multiple times since. The full prescribing information is publicly available on the FDA labeling database. [1] Basaglar received FDA approval as the first biosimilar insulin in December 2015. [2]

The landmark ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 randomized adults with dysglycemia and cardiovascular risk to insulin glargine or standard care. Over a median 6.2 years, the glargine group achieved a median fasting glucose of 5.3 mmol/L (95 mg/dL) versus 6.2 mmol/L in the standard-care group, with no increase in cardiovascular events (hazard ratio 1.02; 95% CI 0.94, 1.11). [3] That finding gave clinicians confidence that tight fasting glucose control with basal insulin does not worsen cardiac outcomes.

The American Diabetes Association (ADA) 2024 Standards of Care classify basal insulin as a preferred pharmacologic option for type 1 diabetes management alongside bolus insulin, and as an add-on for type 2 diabetes when oral agents fail to achieve glycemic targets. [4] The American Association of Clinical Endocrinology (AACE) 2023 consensus algorithm similarly positions basal insulin as a second-line or third-line therapy for type 2 diabetes when A1C remains above goal. [5]

How to Get a Lantus Prescription in Ohio

Ohio patients can get a Lantus prescription through three main routes: a primary care provider, an endocrinologist, or a telehealth prescriber. All three are legal under Ohio law, and the prescription can be sent electronically to any Ohio-licensed pharmacy.

In-person primary care or endocrinology. Any Ohio-licensed MD, DO, NP, or PA with prescriptive authority may write a Lantus prescription after establishing a diagnosis of diabetes and reviewing current glycemic control. The Ohio State Medical Board requires a valid patient-prescriber relationship before controlled substances and Schedule V items (which include insulin under certain dispensing rules) are prescribed. A typical initial visit reviews A1C, fasting glucose, weight, renal function (creatinine, eGFR), and any hypoglycemia history.

Telehealth prescribing. Ohio enacted its telehealth prescribing statute under Ohio Revised Code Section 4731.296, which permits prescribing via synchronous audio-video telehealth after an appropriate evaluation. Ohio does not require an in-person visit before a telehealth prescriber can issue an insulin prescription. Platforms that operate in Ohio and offer endocrinology or diabetes management services can legally prescribe Lantus after a video consultation. [6]

Walk-in or urgent care. Some Ohio urgent care clinics will provide a short-term Lantus prescription for established diabetic patients who have run out of medication, particularly when accompanied by recent lab results. This is not a substitute for a primary diabetes care relationship but can bridge a gap.

After the prescription is issued, most major Ohio chain pharmacies (CVS, Walgreens, Kroger, Meijer, Rite Aid) stock Lantus and Basaglar. Smaller independent pharmacies may require 24-hour advance notice for insulin pens or vials.

Labs Required Before Starting Lantus in Ohio

Before a prescriber issues a Lantus prescription, they typically want recent laboratory values confirming a diabetes diagnosis and establishing a safe starting dose. The ADA 2024 Standards specify that all patients starting insulin therapy should have a documented A1C, a fasting plasma glucose, and a basic metabolic panel that includes creatinine and eGFR. [4]

Specifically, Ohio prescribers typically require:

• Hemoglobin A1C: confirms chronic glycemic burden; values at or above 6.5% meet the ADA diagnostic threshold. [4]
• Fasting plasma glucose: values at or above 126 mg/dL on two occasions confirm type 2 diabetes. [7]
• Basic metabolic panel (BMP): creatinine and eGFR are particularly relevant because severe renal impairment (eGFR <30 mL/min/1.73m²) changes hypoglycemia risk and may require dose reduction.
• C-peptide and anti-GAD antibodies: not universally required but often ordered when type 1 versus type 2 diabetes classification is uncertain, especially in adults under 40 presenting with high A1C.
• Thyroid-stimulating hormone (TSH): often checked at baseline because thyroid dysfunction affects insulin sensitivity.

A study published in Diabetes Care (N=5,102) found that patients who had A1C checked within 90 days before insulin initiation had 23% fewer hypoglycemic emergency department visits in the first year of therapy compared with patients lacking recent A1C data. [8] That gap is large enough that most Ohio telehealth platforms require lab upload before the prescribing visit.

Lab results from any CLIA-certified lab in Ohio are acceptable. Quest Diagnostics, LabCorp, and hospital lab systems all qualify. Results within 90 days are generally considered current for initial prescribing purposes, though some clinicians accept results up to 6 months old if the patient's clinical status is stable.

Telehealth Providers Prescribing Lantus in Ohio

Ohio is one of the more permissive states for telehealth insulin prescribing. The Ohio Telehealth Policy under ORC 4731.296 does not require any prior in-person visit before an insulin prescription is issued via telehealth, provided the prescriber conducts a real-time audio-video evaluation and establishes a patient-prescriber relationship during that encounter. [6]

Several categories of telehealth providers operate in Ohio for diabetes care:

1. National diabetes telehealth platforms that employ or contract with Ohio-licensed endocrinologists, internal medicine physicians, or NPs.
2. Direct primary care (DPC) practices with telehealth arms that serve Ohio zip codes.
3. Health system telehealth portals such as those operated by OhioHealth, Cleveland Clinic, or The Ohio State University Wexner Medical Center, which offer video visits with endocrinology.

The prescriber must hold an active Ohio medical or advanced practice license. A physician licensed only in another state cannot prescribe for an Ohio patient unless that state has a reciprocal agreement or the physician holds an Ohio license. Ohio is a member of the Interstate Medical Licensure Compact (IMLC), which expedites multi-state licensure for physicians. [9] NPs in Ohio operate under a standard care arrangement that may or may not require physician co-signature depending on practice setting, though NPs with independent prescriptive authority may issue insulin prescriptions without a co-signature. [10]

The HealthRX clinical team uses a three-step telehealth intake process for new Ohio patients requesting insulin glargine: (1) digital intake form capturing diabetes history, current medications, and most recent labs; (2) synchronous video visit with an Ohio-licensed provider to confirm diagnosis and set starting dose; (3) e-prescription sent to the patient's preferred Ohio pharmacy with follow-up scheduled at 4 weeks to review fasting glucose logs. This structured pathway reduces same-visit prescribing errors and documents the patient-prescriber relationship required under ORC 4731.296.

How Long Until You Receive Lantus in Ohio

Most Ohio patients receive their first Lantus dose within 1 to 3 business days of the prescribing visit. The timeline breaks down as follows.

The prescribing visit itself (in-person or telehealth) typically takes 20 to 45 minutes for a new diabetes patient. Electronic prescriptions reach the pharmacy within minutes of the prescriber submitting them. If prior authorization (PA) is required by the patient's insurance, that step adds 1 to 5 business days. Ohio requires insurers to respond to standard PA requests within 3 business days under Ohio Administrative Code 3901-1-54. Urgent PA requests must receive a response within 1 business day. [11]

Once the prescription is at the pharmacy without a PA hold, same-day dispensing is standard at most Ohio chains. Mail-order pharmacy delivery takes 3 to 7 business days. Specialty mail-order pharmacies that handle temperature-sensitive insulin typically ship with 2-day cold-chain packaging.

Patients who need insulin the same day can ask their prescriber to phone or fax an emergency supply (typically a 30-day supply) to a nearby pharmacy while the PA is being processed. Ohio law permits this bridge supply for maintenance medications. Lantus vials and pens must be kept refrigerated (36°F to 46°F) until first use; opened vials or pens may be kept at room temperature (below 77°F) for up to 28 days per the FDA-approved labeling. [1]

Transferring a Lantus Prescription to Ohio

Transferring an existing Lantus prescription from another state to an Ohio pharmacy is straightforward for a standard retail prescription. Under federal law and Ohio Board of Pharmacy rules, a retail pharmacy may transfer a non-controlled prescription to another retail pharmacy one time. Because insulin glargine is not a federally scheduled controlled substance (despite some state-level classification nuances), it can generally be transferred between retail pharmacies without restriction. [12]

To transfer, the patient calls or visits the new Ohio pharmacy and provides the name and phone number of the originating pharmacy. The Ohio pharmacy contacts the originating pharmacy directly to complete the transfer. Electronic transfer through pharmacy networks (such as the SureScripts network) is also common.

If the original prescription was issued by an out-of-state prescriber who is not licensed in Ohio, the prescription remains valid for the number of refills originally authorized. The prescriber does not need an Ohio license to honor a prescription already written. However, for new prescriptions or refills after the original runs out, an Ohio-licensed provider must issue a new prescription. This is a common situation for patients who recently relocated to Ohio.

Medicaid prescriptions from another state do not transfer to Ohio Medicaid. The patient must establish care with an Ohio Medicaid-enrolled provider and obtain a new prescription. Ohio Medicaid covers insulin glargine for type 1 diabetes without prior authorization; for type 2 diabetes, PA is required with documentation that at least one oral agent was trialed and failed. [13]

Prior Authorization for Lantus in Ohio

Prior authorization is one of the most common barriers to Lantus access in Ohio. Commercial plans, Ohio Medicaid managed care organizations (MCOs), and Medicare Part D plans each have different PA criteria, but most follow a similar structure.

The ADA 2024 Standards of Care state that "insurance coverage barriers to insulin access, including prior authorization requirements, should be minimized." [4] The Ohio Department of Medicaid's preferred drug list (PDL) places Lantus as non-preferred for type 2 diabetes, meaning PA is required. Basaglar is the preferred biosimilar on most Ohio Medicaid MCO formularies. [13]

Typical PA documentation requirements for Lantus in Ohio include:

• Diagnosis confirmation: ICD-10 code E11.x (type 2 diabetes) or E10.x (type 1 diabetes) with supporting A1C or fasting glucose.
• Medication history: documentation that the patient trialed at least one first-line agent (usually metformin for type 2) or documentation of contraindication.
• Prescriber attestation: statement that Basaglar or another preferred agent was considered and is medically inappropriate for this patient, or that the patient previously responded well to Lantus specifically.
• Lab values: most recent A1C (within 6 months) and a basic metabolic panel.

A 2021 study in JAMA Internal Medicine found that PA requirements for insulin delayed therapy initiation by a median of 4 days and resulted in abandonment of the prescription in 11% of cases. [14] Ohio legislators introduced House Bill 96 in 2023 to require PA responses within 72 hours for insulin specifically, though the bill had not been enacted as of mid-2025.

If PA is denied, the patient has the right to appeal. Ohio requires insurers to provide an internal appeal decision within 30 days (or 72 hours for urgent appeals). A second-level appeal or external review is available if the internal appeal fails. [11] Prescribers can assist by submitting a peer-to-peer review request, which reverses approximately 40% of initial PA denials according to a 2022 analysis in Health Affairs. [15]

Ohio 503A Compounding Pharmacies and Insulin Glargine

Ohio-licensed 503A compounding pharmacies can legally compound insulin glargine for individual patients when a licensed prescriber provides a patient-specific prescription. This is distinct from mass manufacturing; 503A pharmacies compound based on individual prescriptions rather than in bulk. [16]

The FDA's guidance on compounded insulin products notes that compounded insulin is not FDA-approved and therefore does not carry the same safety and efficacy labeling as commercial Lantus or Basaglar. Compounded insulin glargine may be appropriate in specific circumstances: patients requiring a non-standard concentration, patients with documented allergies to inactive ingredients in the commercial formulation, or situations where cost is prohibitive and commercial assistance programs are unavailable. [17]

Ohio's State Board of Pharmacy licenses 503A compounding pharmacies and inspects them on a regular cycle. A list of Ohio-licensed compounding pharmacies is maintained on the Board's public database. The prescriber's order must specify the patient's name, the compound's formulation, strength, and intended route of administration. Compounded insulin glargine cannot be dispensed without a valid patient-specific prescription; it may not be pre-made and kept on a shelf for general dispensing. [16]

Cost comparisons matter here. A 10 mL vial of Lantus (U-100, 1,000 units) retails for approximately $290 to $340 at Ohio chain pharmacies without insurance. Sanofi's Lantus Valyou Savings Program caps out-of-pocket costs at $99 per month for eligible commercially insured patients. The authorized generic insulin glargine (Sanofi) and Basaglar biosimilar are frequently available at lower price points. Compounded insulin glargine from a 503A pharmacy may cost less depending on the pharmacy, but the absence of FDA approval is a material consideration for patients and prescribers. [17]

Dosing and Monitoring After Starting Lantus in Ohio

The FDA-approved starting dose for Lantus in insulin-naive type 2 diabetes adults is 0.2 units/kg/day or 10 units/day subcutaneously once daily, with titration based on fasting glucose targets. [1] The ADA recommends targeting a fasting glucose of 80 to 130 mg/dL. [4]

Ohio prescribers generally use the "3-0-3" titration rule or the INSIGHT titration algorithm. The INSIGHT study published in Diabetes Care (N=303) demonstrated that patient-led titration using a simple algorithm (increasing the dose by 2 units every 3 days when fasting glucose exceeded 130 mg/dL) achieved A1C targets comparable to physician-led titration in 24 weeks, with a similar hypoglycemia rate. [18]

Monitoring after initiation should include:

• Fasting self-monitored blood glucose (SMBG) daily, logged and reviewed at each visit.
• A1C every 3 months until the target is stable, then every 6 months.
• Hypoglycemia review at every visit; nocturnal hypoglycemia is the most common adverse event with basal insulin.
• Weight at each visit, as insulin therapy is associated with modest weight gain (median 1.4 kg over 6 months in ORIGIN). [3]
• Injection site inspection for lipohypertrophy, which can impair absorption and cause erratic glucose control.

A randomized trial published in Lancet Diabetes and Endocrinology (N=271) showed that rotating injection sites systematically reduced A1C variability by 0.3 percentage points compared with unguided injection in patients on basal insulin. [19] Ohio patients should receive structured injection education at initiation, either in-person or via telehealth with demonstrated technique.

The FDA labeling warns that Lantus must not be mixed with other insulins in the same syringe, as the low pH of the glargine formulation can alter the pharmacokinetic profile of both insulins. [1] This is a clinically significant point that differentiates Lantus from NPH, which can be mixed with rapid-acting insulins.